Results 131 to 140 of about 49,882 (187)
Some of the next articles are maybe not open access.
Current Opinion in Oncology, 2001
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
M J, Mauro, B J, Druker
+7 more sources
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia.
M J, Mauro, B J, Druker
+7 more sources
Current Opinion in Hematology, 1995
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Chronic myelogenous leukemia involves clonal expansion of hematopoietic progenitor cells associated with the characteristic translocation between chromosomes 9 and 22, resulting in the generation of an aberrant bcr-abl protein with enhanced tyrosine kinase activity.
H, Enright, P B, McGlave
openaire +3 more sources
Current Opinion in Hematology, 1999
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Hematology, 2002
Abstract The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed.
Brian J, Druker +3 more
openaire +2 more sources
Abstract The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed.
Brian J, Druker +3 more
openaire +2 more sources
Current Opinion in Oncology, 1994
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
J E, Cortes, S, O'Brien
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 1998
The incidence of acute myelogenous leukaemia (AML) increases steadily with age, more than 50% of the cases being diagnosed in subjects aged 60 years or over [1,2]. Age has been reported as an adverse prognostic indicator in AML affecting both remission rates and survival [1–3].
A, Pinto, G B, Zulian, E, Archimbaud
openaire +2 more sources
The incidence of acute myelogenous leukaemia (AML) increases steadily with age, more than 50% of the cases being diagnosed in subjects aged 60 years or over [1,2]. Age has been reported as an adverse prognostic indicator in AML affecting both remission rates and survival [1–3].
A, Pinto, G B, Zulian, E, Archimbaud
openaire +2 more sources
CONGENITAL MYELOGENOUS LEUKEMIA
Archives of Pediatrics & Adolescent Medicine, 1950Leukemia in the newborn is rare and unique in that it is almost invariably of the myelogenous type. Kelsey and Anderson,1in a comprehensive survey of the literature up to 1939, collected 17 reported cases of congenital leukemia. Of these, they accepted only 9 as instances of unquestionable congenital leukemia, the remaining 8 cases being probable ...
F M, TAYLOR, L J, GEPPERT
openaire +2 more sources
Experimental Hematology, 2009
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua L, Shipley, James N, Butera
openaire +2 more sources
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua L, Shipley, James N, Butera
openaire +2 more sources
Photochemotherapy of myelogenous and non-myelogenous tumor cells
ICALEO '88: Proceedings of the Laser Research in Medicine, Dentistry & Surgery Conference, 1988Dye mediated laser photoradiation therapy was tested in an in vitro model for its efficacy to eliminate occult tumor cells for ex vivo autologous bone marrow purging. Merocyanine 540 was mixed with leukemia, lymphoma, small cell lung carcinoma, and multiple myeloma cells supplemented with 0.25% human albumin. This cell-dye mixture was exposed to 514 nm
Kirpal S. Gulliya, A. Edward Profio
openaire +1 more source